Research programme: PDGF - Seattle Life Sciences
Alternative Names: PDGF-C; PDGF-D; Platelet derived growth factor; Zvegf4Latest Information Update: 07 Jan 2022
At a glance
- Originator ZymoGenetics
- Developer Seattle Life Sciences
- Class Antineoplastics; Antiulcers; Growth factors; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Sep 2010 Discontinued - Preclinical for Undefined indication in USA (Parenteral)
- 05 May 2009 Preclinical trials in Undefined indication in USA (Parenteral)
- 05 Aug 2002 Preclinical trials in Fracture in USA (unspecified route)